Skip to content

Effects of Remimazolam, Propofol, and Sevoflurane on Serum Neutrophil Extracellular Trap Markers and Inflammatory Cytokines in Patients with Non-Small Cell Lung Cancer After Surgery: A Prospective Randomized Controlled Trial

Effects of Remimazolam, Propofol, and Sevoflurane on Serum Neutrophil Extracellular Trap Markers and Inflammatory Cytokines in Patients with Non-Small Cell Lung Cancer After Surgery: A Prospective Randomized Controlled Trial

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600119997
Enrollment
Unknown
Registered
2026-03-06
Start date
2026-03-08
Completion date
Unknown
Last updated
2026-03-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung cancer

Interventions

Sponsors

The Fourth Affiliated Hospital of Soochow University (Suzhou Dushu Lake Hospital)
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Patients with a preoperative diagnosis of non-small cell lung cancer scheduled for elective thoracoscopic surgery under general anesthesia; 2. ASA physical status classification I-III; 3. Age 18-80 years; 4. Voluntary participation and signed informed consent; 5. Agreement to use a postoperative analgesic pump.

Exclusion criteria

Exclusion criteria: 1. Severe cardiopulmonary insufficiency; 2. History of neoadjuvant chemotherapy, targeted therapy, or immunotherapy; 3. Autoimmune disease or chronic inflammation; 4. Systemic infection or corticosteroid use within 1 month prior to surgery; 5. Neutropenia ( 442 µmol/L or undergoing renal replacement therapy); 8. Neuropsychiatric disorders precluding informed consent; 9. Pregnant women; 10. Patients with tumors at other sites or those with metastatic disease.

Design outcomes

Primary

MeasureTime frame
Serum NETosis-Specific Marker (MPO);

Secondary

MeasureTime frame
Serum NETosis-Specific Marker (Citrullinated Histone H3);Inflammatory cytokines (IL-6, IL-8, IL-10);Postoperative pain status; Postoperative recovery quality;Hemodynamic data (intraoperative mean arterial pressure, heart rate);Incidence of PONV within 24 hours postoperatively;hospital stay after operation;Extubation timing and PACU stay duration;Intraoperative Use of Vasoactive Drugs;Incidence of postoperative pulmonary complications and adverse events (including intraoperative awareness; delayed emergence from anesthesia; deep vein thrombosis of the lower extremities; wound infection, etc.).;

Countries

China

Contacts

Public ContactLi Jian

The Fourth Affiliated Hospital of Soochow University (Suzhou Dushu Lake Hospital)

kentleesz@suda.edu.cn+86 137 7170 4822

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Mar 14, 2026